8QZ4

Crystal structure of human two pore domain potassium ion channel TREK-2 (K2P10.1) in complex with an activatory nanobody (Nb76)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.298 
  • R-Value Work: 0.270 
  • R-Value Observed: 0.272 

Starting Models: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Extracellular modulation of TREK-2 activity with nanobodies provides insight into the mechanisms of K2P channel regulation.

Rodstrom, K.E.J.Cloake, A.Sormann, J.Baronina, A.Smith, K.H.M.Pike, A.C.W.Ang, J.Proks, P.Schewe, M.Holland-Kaye, I.Bushell, S.R.Elliott, J.Pardon, E.Baukrowitz, T.Owens, R.J.Newstead, S.Steyaert, J.Carpenter, E.P.Tucker, S.J.

(2024) Nat Commun 15: 4173-4173

  • DOI: https://doi.org/10.1038/s41467-024-48536-2
  • Primary Citation of Related Structures:  
    8QZ1, 8QZ2, 8QZ3, 8QZ4

  • PubMed Abstract: 

    Potassium channels of the Two-Pore Domain (K2P) subfamily, KCNK1-KCNK18, play crucial roles in controlling the electrical activity of many different cell types and represent attractive therapeutic targets. However, the identification of highly selective small molecule drugs against these channels has been challenging due to the high degree of structural and functional conservation that exists not only between K2P channels, but across the whole K + channel superfamily. To address the issue of selectivity, here we generate camelid antibody fragments (nanobodies) against the TREK-2 (KCNK10) K2P K + channel and identify selective binders including several that directly modulate channel activity. X-ray crystallography and CryoEM data of these nanobodies in complex with TREK-2 also reveal insights into their mechanisms of activation and inhibition via binding to the extracellular loops and Cap domain, as well as their suitability for immunodetection. These structures facilitate design of a biparatropic inhibitory nanobody with markedly improved sensitivity. Together, these results provide important insights into TREK channel gating and provide an alternative, more selective approach to modulation of K2P channel activity via their extracellular domains.


  • Organizational Affiliation

    Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Potassium channel subfamily K member 10
A, B
282Homo sapiensMutation(s): 0 
Gene Names: KCNK10TREK2
Membrane Entity: Yes 
UniProt & NIH Common Fund Data Resources
Find proteins for P57789 (Homo sapiens)
Explore P57789 
Go to UniProtKB:  P57789
PHAROS:  P57789
GTEx:  ENSG00000100433 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP57789
Sequence Annotations
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 2
MoleculeChains Sequence LengthOrganismDetailsImage
Nanobody 76
C, D
123Lama glamaMutation(s): 0 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Y01
Query on Y01

Download Ideal Coordinates CCD File 
G [auth A],
H [auth A],
I [auth A],
L [auth B]
CHOLESTEROL HEMISUCCINATE
C31 H50 O4
WLNARFZDISHUGS-MIXBDBMTSA-N
BA
Query on BA

Download Ideal Coordinates CCD File 
E [auth A],
F [auth A],
J [auth B],
K [auth B]
BARIUM ION
Ba
XDFCIPNJCBUZJN-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.20 Å
  • R-Value Free: 0.298 
  • R-Value Work: 0.270 
  • R-Value Observed: 0.272 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 68.28α = 90
b = 75.576β = 90
c = 259.15γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
Aimlessdata scaling
STARANISOdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Biotechnology and Biological Sciences Research Council (BBSRC)United KingdomBB/T002018/1
Biotechnology and Biological Sciences Research Council (BBSRC)United KingdomBB/S008608/1
Medical Research Council (MRC, United Kingdom)United KingdomMR/W017741/1
Grenoble Instruct-ERIC Center (ISBG)France--
Research Foundation - Flanders (FWO)Belgium--
Wellcome TrustUnited Kingdom106169/Z/14/Z
Wellcome TrustUnited KingdomWT084655MA
Wellcome TrustUnited Kingdom102161/B/13/Z

Revision History  (Full details and data files)

  • Version 1.0: 2024-05-29
    Type: Initial release
  • Version 1.1: 2024-11-06
    Changes: Structure summary